NCT06729853View on ClinicalTrials.gov

PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

January 17, 2025

Study Completion Date

April 28, 2025

Conditions

GoutHyperuricemia

Interventions

DRUG

SAP-001

a single oral dose of SAP-001

Trial Locations (2)

33603

Genesis Clinical Research, Tampa

55114

Nucleus Network Pty Ltd, Saint Paul

All Listed Sponsors

lead

Shanton Pharma Pte. Ltd.

INDUSTRY